CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 164 filers reported holding CLOVIS ONCOLOGY INC in Q4 2015. The put-call ratio across all filers is 0.74 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $91,000 | -69.4% | 18,924 | -62.9% | 0.00% | -100.0% |
| Q3 2020 | $297,000 | +133.9% | 51,011 | +171.8% | 0.00% | – |
| Q2 2020 | $127,000 | +15.5% | 18,770 | +8.8% | 0.00% | – |
| Q1 2020 | $110,000 | +129.2% | 17,249 | +433.2% | 0.00% | – |
| Q2 2019 | $48,000 | -82.0% | 3,235 | -36.1% | 0.00% | -100.0% |
| Q1 2018 | $267,000 | -22.6% | 5,060 | -0.3% | 0.00% | -50.0% |
| Q4 2017 | $345,000 | -20.5% | 5,073 | -3.6% | 0.00% | 0.0% |
| Q3 2017 | $434,000 | -9.0% | 5,261 | +3.3% | 0.00% | -33.3% |
| Q2 2017 | $477,000 | +49.5% | 5,093 | +1.7% | 0.00% | +50.0% |
| Q1 2017 | $319,000 | +10.8% | 5,010 | +60.2% | 0.00% | -33.3% |
| Q3 2015 | $288,000 | +14.7% | 3,127 | +9.7% | 0.00% | 0.0% |
| Q2 2015 | $251,000 | +16.2% | 2,851 | -2.1% | 0.00% | +50.0% |
| Q1 2015 | $216,000 | – | 2,912 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $45,630,648,000 | 43.63% |
| EcoR1 Capital, LLC | 384,348 | $21,523,000 | 10.89% |
| Palo Alto Investors LP | 2,102,857 | $117,760,000 | 6.91% |
| NEA Management Company, LLC | 2,279,781 | $127,668,000 | 6.19% |
| Redmile Group, LLC | 721,632 | $40,411,000 | 4.40% |
| Opaleye Management Inc. | 140,000 | $7,840,000 | 3.96% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 790,555 | $44,271,000 | 2.63% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 339,327 | $19,002,000 | 2.31% |
| PFM Health Sciences, LP | 1,725,126 | $96,607,000 | 2.26% |
| HARBOURVEST PARTNERS LLC | 51,037 | $2,858,000 | 1.50% |